About GBB

Global Bioprocessing Made Simpler and More Efficient

About GBB

Home/About GBB

Company Profile

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Global Bioprocessing Made Simpler and More Efficient. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, as well as other industries involving bioprocessing (e.g. Synthetic Biology, IVD, CGT, etc.) . Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States.

GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

As of the end of 2022, GBB has completed three financing rounds, raising over US $30 million.

Culture

Vision

Global Bioprocessing Made Simpler and More Efficient

Mission

Challenging the Future with 3D Innovation

Values

Innovation, Execution, Leadership

History

Chronicle of events

2023

Awarded the High-Tech Enterprise

Awarded the 2023 Deloitte Rising Star Award

Awarded the EY Entrepreneur Of The Year™ 2023 Awards

Awarded the Second Prize in the Shenzhen Innovation Competition

Great Bay Bio and MNC Kickstart Strategic Cooperation for AI-Driven Cell Culture Media Development

Launched AI-enabled No-screening Cell Culture Media Development Platform, AlfaOPA

BioCon Awards 2023 Top Popular Enterprise of Biotechnology Industry

Won the Gold Award for Hong Kong Global Innovation Awards, and also awarded Excellence in Process Innovation and Excellence in Technology Adoption

Admitted into the HKSTP Elite Programme

Ranked Among Top 100 Future Medical Companies in 2023

BCIC2023 International Biomedical Entrepreneurship Competition • Best Innovation Award

Great Bay Bio and Xinyi Technology Reached Strategic Cooperation

AI-enabled Site-Specific Integration Cell Line Completed DMF filing

Served as Member of Shenzhen Artificial Intelligence Industry Association

Chronicle of events

2022

Awarded Hong Kong Innopreneur Awards – GBA+ Award

AI-enabled Site-Specific Integration Cell Line Development Platform, AlfaCell Was Awarded the Creative Star of Wings

Launched AI-enabled Site-Specific Integration Cell Line Development Platform, AlfaCell

Landed USD 15M Pre-Series B Funding Led by Tiger Jade Capital

Listed on 2022 Spring Semester of Microsoft Acceleration Program

Forged Strategic Alliance with Cheerland Life Science

Forged Strategic Alliance with ChemPartner

Chronicle of events

2021

Joined NVIDIA's Inception Program and Won the Special Prize of NVIDIA Start-up Final Presentation

Completed Series A Fundraising Worth of Nearly USD 10M

Awarded the Gen.T Social Impact and Leader of Tomorrow 2021

Entered Top 15 of 2021 Merck Greater Bay Area Innovation Bootcamp

Entered Hong Kong Science Park

Forged Strategic Alliance with Chime Biologics

Launched AI-enabled Cell Line Stability Prediction Platform, AlfaStaX

Launched AI-enabled Cell Culture Media Database Platform, AlfaMedX

Completed USD 3.8M Convertible Note Financing  Led by Alibaba Hong Kong Entrepreneurs Fund

Chronicle of events

2020

Awarded the Top 50 Innovative Biotechnology Companies

Among the top 150 of the Sprout List and Awarded as One of the Most Valuable Companies for Investment in China in 2020

Awarded the High-Tech Enterprise

Awarded the “Young Industrialist of Hong Kong 2020”

Launched AI-enabled Cell Precision Selection Platform, Klone4.0

Approved to Set Up Doctoral Workstation in Guangdong

Chronicle of events

2019

Signed Memorandum of Cooperation with Pengcheng

Awarded Merit Award for Innovative Hong Kong SME

Injected with USD 2.5M Convertible Note

The Establishment of Great Bay Bio

2023
2022
2021
2020
2019

Board of Directors

Kingsley Leung

Great Bay Bio, Chairman & Co-founder

Kingsley Leung

Great Bay Bio, Chairman & Co-founder

Mr. Leung has over 15 years’ experience in the life science and finance industries. Currently, he is the Chairman of Great Bay Bio and also serves as Director in both Uni-bio Science Group and DotBio.  He has broad experience in sourcing, evaluating and executing new growth opportunities, supporting the execution and alliance management of 8 deals, including the in-licensing of next generation oncology, inflammation and respiratory drugs from MNCs. 

Mr. Leung also has extensive experience in the finance industry where he worked in healthcare investment banking in Merrill Lynch and a family office, helping evaluated IPO opportunities for multiple companies across the US and PRC. Up to date, Mr. Leung has led and successfully raised over USD 60M across multiple of his ventures. Mr. Leung was awarded the prestigious honour of World Outstanding Young Leaders Award from Yazhou Zhoukan in 2016, Entrepreneur of the Year from CAPITAL in 2017, Young Industrialist Awards of Hong Kong in 2020, and Gen.T Social Impact and Leader of Tomorrow 2021.
Mr. Leung is currently a Chartered Financial Analyst and a member of The Hong Kong Society of Financial Analysts. He was also elected the Vice Chairman of Pharmaceutical & Chemical group of the Federation of Hong Kong Industries (FHKI). Mr. Leung holds a BSc in Biochemistry from Imperial College London, an MSc in Pharmacology from the University of Oxford, and EMBA from Tsinghua-INSEAD. In addition, he holds a Professional Diploma in Corporate Governance & Directorship from the HongKong Institute of Directors.


Michael Chen, Ph.D.

Great Bay Bio, CEO & Co-founder

Michael Chen, Ph.D.

Great Bay Bio, CEO & Co-founder

Dr. Michael Chen is the CEO & Co-founder of Great Bay Bio. He has more than 30 years of experience in technologies, operation management, and business partnership in the biopharmaceutical industry. Prior to Great Bay Bio, Dr. Chen served as the senior positions in Synageva, Faville, and Applied Biotech. In the last five years Dr. Chen has led the GBB team to successfully launch several AI-enabled bioprocessing platforms.
Dr. Chen holds a Ph.D. degree in biochemistry from the University of Georgia and a postdoctoral position from The Scripps Research Institute in San Diego. He has received several NIH postdoctoral scholarships and has published 14 SCI papers, and owns more than 50 patents.


George Li

Managing Partner of Proxima Ventures

George Li

Managing Partner of Proxima Ventures

George Li is a Managing Partner with Proxima Ventures. George has over 15 years’ experience of founding, investing and building life science start-up companies and has accumulated hands-on experience of advising and investing early stage medtech companies, specially in interdisciplinary innovations. George led Proxima Ventures investment of  Vickor, Nanoablation, Matridx, Mobidrop, Wisdom Health and serve as boarddirector of those companies.

Prior to joining Proxima Ventures,George founded Biohub which is a leading medical incubator & accelerator in China and has built a leading medical ecosystem which has offices in Wuhan, Suzhou, Zhengzhou, Chongqing and Chengdu to provide wet lab and cGMP facilities and provides access to top hospitals and KOLs in China. Biohub has incubated and supported 100+ early stage life science companies covering biotech, medical devices, diagnostic and medical services.

Prior to Biohub, George was co-founder of Biohermsand grew it into a leading IVD company in China.

George also serves as the Chair judge for Chunhui business plan contest and mentor early stage companies.

George holds a MBA from Hult International Business School and a Bachelor degree from Zhejiang University.

Chibo Tang

Managing Partner of Gobi

Chibo Tang

Managing Partner of Gobi

Chibo Tang, Managing Partner of Gobi has been investing in tech startups in China for over a decade. He is Head of Gobi’s Greater Bay Area (GBA) practice, and manages the Alibaba Hong Kong Entrepreneurs Fund (AHKEF) for which Gobi is the exclusive General Partner (GP).  He has led numerous investments including Airwallex, WeLab, GOGOX, AutoX, Amber Group, Animoca Brands, Prenetics, OneDegree, Urban Revivo, DayDayCook, AQUMON, SHOPLINE, and SandboxVR.  

Chibo is recognized in the industry as Silicon Dragon Venture Capitalist of the Year 2017, Top 25 Global Corporate Venturing Rising Star 2019, Top 10 Global Corporate Venturing Emerging Leader 2020, a member of Generation T Asia Tatler Tribe as well as Asia’s Most Influential 2021, and is an Advisory Council Member of the Asia Technology Entrepreneurship Conference.

Chibo received his B.A. in Applied Mathematics and Economics from Harvard College, and received his MBA in Finance from China Europe International Business School (CEIBS). Chibo began his career as Strategy Consultant with Monitor Group, focusing on ASEAN and MENA region, then spent time at Robert Bosch as Senior Manager of Corporate Strategy APAC. Chibo joined Gobi Partners in 2009 and is currently a Managing Partner based in Hong Kong.

Jack Wang

Partner of Tiger Jade Capital

Jack Wang

Partner of Tiger Jade Capital

Mr. Jack Wang is currently partner of Tiger Jade Capital where he sits in investment committee and is also responsible for overall investor relationship. From June 2017 to January, 2022, Mr. Wang served as a Managing Director at CMB International Asset Management Limited (“CMBI), where he led the firms effort in various notable investments including Tencent Music Entertainment Group, Xiaomi Corporation, and Grab Holdings Inc., etc and worked closely with the firms healthcare team and participated in project fund investing in leading healthcare companies in China, such as Burning Rock Biotech Limited and Biocytogen Pharmaceuticals (Beijing) Co., Ltd.


Prior to joining CMBI, Mr. Wang worked at CSOP Asset Management Limited from April 2012 to August 2016 with his last position being the Deputy Chief Marketing Officer, where he was instrumental in building the firm to become the largest RMB QFII player in the market. Mr. Wang also worked at Deutsche Securities Asia and Goldman Sachs (Asia) L.L.C. from November 2006 to March 2012.


Mr. Wang obtained a Bachelor’s Degree in Economics from Tsinghua University in July 2006.

Ting Xie (Observer), Ph.D., CFA

Managing Director of Hillhouse Capital

Ting Xie (Observer), Ph.D., CFA

Managing Director of Hillhouse Capital

Dr. Ting Xie from Hillhouse BioVenture, focuses onthe investment of cutting edge life science technologies and new therapies globally, he serves as a Board Member at various biotech companies including Elpiscience. Prior to that he worked for a Healthcare specialized Private Equity fund HCR in New York metro area and a Wall Street financial institution Alliance Bernstein covering Biotech and Spec Pharma. He obtained a Ph.D. degreefrom Harvard University, and BS degree from Tsinghua University.


Management Team

Kane Qi, Ph.D.

Chief Commercial Officer

Kane Qi, Ph.D.

Chief Commercial Officer

Dr. Qi graduated from East China University of Science and Technology, majoring in biochemical engineering. He has conducted research in synthetic biology and metabolic engineering at the State Key Laboratory of Bioreactor Engineering (East China University of Science and Technology) and the State Key Laboratory of Microbial Metabolism (Shanghai Jiao Tong University). Dr. Qi has many years of experience in commercializing innovative products and rich experience in market management, business model innovation and business team building for technical products such as big data statistics, mass spectrometry multi omics tools and single cell analysis.


Hongjiang Miao, Ph.D.

Chief Technology Officer (AI)

Hongjiang Miao, Ph.D.

Chief Technology Officer (AI)

Dr. Hongjiang Miao has over ten years of experience in AI+Biocomputing project development and team management. His team developed the first high-precision 3D protein structure prediction algorithm as well as the first AIGC protein design workbench in China, which won numerous awards including Shanghai Pujiang Talent, Shanghai’s Top10 Major AI Events of 2021, and the Second Prize of Digital Transformation in AI+New Drug Research, Development and Manufacturing in Shanghai. 
Dr. Miao graduated from Oxford University with a bachelor and master's degree in mathematics and statistics. During his doctoral studies at Imperial College London, he was supervised by Professor Michael J.E. Sternberg, a fellow of the Royal Society of Biology, to develop algorithms for protein structure and function prediction.


Kenneth Lai

Chief Financial Officer

Kenneth Lai

Chief Financial Officer


Mr. Kenneth Lai possesses extensive expertise in financial management within the biotech and medical device industries, bringing over 20 years of experience in various key areas such as private and public equity fund raising, establishing foundational finance, and legal & compliance functions. . Notably, he has demonstrated his leadership abilities by overseeing the successful completion of two Hong Kong IPOs for prominent biotech companies.
With honors, Mr. Kenneth Lai obtained his degree in finance and accounting from Simon Fraser University in Canada. He is a qualified Canadian chartered accountant and has garnered valuable experience in auditing and consulting through his tenure at reputable Big Four accounting firms, including PwC and KPMG. Currently, Mr. Lai is actively pursuing an executive MBA program at the esteemed Kellogg School of Management in conjunction with the Hong Kong University of Science and Technology, further enriching his knowledge and skill set.



Wanjun Lan

Vice President of CMC

Wanjun Lan

Vice President of CMC

Mr. Lan has more than 15 years of experience in new drug screening, process development and scale-up, quality research, registration and clinical project management. Mr. Lan used to work in drug screening at the Key Laboratory of Animal Resources and Disease Prevention and Control in Liaoning Province, in drug research and development department at Sailong Pharmaceutical Group (002898), and successively served as an analysis supervisor, a quality manager, and a R&D executive manager in a subsidiary of Uni-Bio Science (HK690). Mr. Lan successively served as R&D director and general manager at Guangzhou Tailli Biomedicine Co., Ltd.
Mr. Lan holds a master's degree in biochemistry and molecular biology, a bioengineer, an authorized person for drug production quality, and has published more than 20 papers and patents.

Company Honors

BioCon Awards 2023 Top Popular Enterprise of Biotechnology Industry

The Gold Award for Hong Kong Global Innovation Awards

Excellence in Process Innovation for Hong Kong Global Innovation Awards

Excellence in Technology Adoption for Hong Kong Global Innovation Awards

Admitted into the HKSTP Elite Programme

Ranked Among Top 100 Future Medical Companies in 2023

BCIC2023 International Biomedical Entrepreneurship Competition • Best Innovation Award

Served as Member of Shenzhen Artificial Intelligence Industry Association

Hong Kong Innopreneur Awards – GBA+ Award

AlfaCell® Was Awarded the Creative Star of Wings

Listed on 2022 Spring Semester of Microsoft Acceleration Program

GBB Successfully Joined NVIDIA's Inception Program and Won the Special Prize of NVIDIA Start-up Final Presentation

Awarded the Gen.T Social Impact and Leader of Tomorrow 2021

Entered Top 15 of 2021 Merck Greater Bay Area Innovation Bootcamp

Awarded the Top 50 Innovative Biotechnology Companies

Awarded the High-Tech Enterprise

Awarded the “Young Industrialist of Hong Kong 2020”

Approved to Set Up Doctoral Workstation in Guangdong

Awarded Merit Award for Innovative Hong Kong SME

BioCon Awards 2023 Top Popular Enterprise of Biotechnology Industry

The Gold Award for Hong Kong Global Innovation Awards

Excellence in Process Innovation for Hong Kong Global Innovation Awards

Excellence in Technology Adoption for Hong Kong Global Innovation Awards

Admitted into the HKSTP Elite Programme

Ranked Among Top 100 Future Medical Companies in 2023

BCIC2023 International Biomedical Entrepreneurship Competition • Best Innovation Award

Served as Member of Shenzhen Artificial Intelligence Industry Association

Hong Kong Innopreneur Awards – GBA+ Award

AlfaCell® Was Awarded the Creative Star of Wings

Listed on 2022 Spring Semester of Microsoft Acceleration Program

GBB Successfully Joined NVIDIA's Inception Program and Won the Special Prize of NVIDIA Start-up Final Presentation

Awarded the Gen.T Social Impact and Leader of Tomorrow 2021

Entered Top 15 of 2021 Merck Greater Bay Area Innovation Bootcamp

Awarded the Top 50 Innovative Biotechnology Companies

Awarded the High-Tech Enterprise

Awarded the “Young Industrialist of Hong Kong 2020”

Approved to Set Up Doctoral Workstation in Guangdong

Awarded Merit Award for Innovative Hong Kong SME

Ecosystem Traction

Investors

Message